ZJ | carboxylic acids and derivatives d-out qh |
NT | +ZK lipids, fatty acids, fats and oils qh ah | |
BT | +ZDe organic compounds qh ah |
ZJ2e | carboxylic acid qh |
ZJ2.2e | . acyclic carboxylic acid qh |
NT | +ZJ2.6.4e acetic acid qh ah |
ZJ2.4e | . methylphenydate qh |
BT | +YP10.8.10 agents for cocaine-concurrent mental disorders qh ah |
ZJ2.6e | . saturated carboxylic acid qh |
ST | carboxylic acid ester |
ZJ2.6.2e | . . formic acid qh |
ST | methanoic acid |
ZJ2.6.2.2e | . . . formate qh |
ZJ2.6.2.2.2e | . . . . ethyl formate qh |
ST | formic acid ethyl ester | |
RT | +BX2.2.4e congener qh ah |
ZJ2.6.4e | . . acetic acid qh |
ST | ethanoic acid | |
BT | +ZJ2.2e acyclic carboxylic acid qh ah | |
+ZK4.8e volatile fatty acid qh ah | ||
RT | +ZN2.20.2.2e acetamide qh ah |
ZJ2.6.4.2e | . . . acetate qh |
RT | EB10.12.8e ethanol metabolite qh ah |
ZJ2.6.4.2.2e | . . . . acetic acid ester qh |
ZJ2.6.4.2.2.2e | . . . . . ethyl acetate qh |
RT | +BX2.2.4e congener qh ah |
ZJ2.6.4.4e | . . . trichloroacetic acid qh |
ZJ2.6.6e | . . propionic acid qh |
ST | propanoic acid | |
BT | +ZK4.8e volatile fatty acid qh ah |
ZJ2.6.6.2e | . . . propionate qh |
ZJ2.6.6.2.2e | . . . . propoxyphene qh |
ST | dextropropoxyphene | |
BT | +BT6.8.6 schedule IV opioids qh ah | |
+YW4.2e narcotic analgesics qh ah | ||
+ZQ18e synthetic opioids qh ah |
ZJ2.6.8e | . . ibuprofen qh |
BT | +YP4.2e anti-alcohol-intoxication agents qh ah |
ZJ2.6.10e | . . butyric acid qh |
ST | butanoic acid | |
BT | +ZK4.8e volatile fatty acid qh ah |
ZJ2.6.10.2e | . . . butyrate qh |
ZJ2.6.10.2.2e | . . . . aminobutyric acid qh |
BT | +YV4 neuroregulators qh ah | |
+ZO2e amino acids qh ah |
ZJ2.6.10.2.2.2e | . . . . . GABA qh |
ST | gamma-aminobutyric acid | |
BT | +YJ2e neurotransmitters qh ah | |
RT | +YK6.8e GABA receptors qh ah | |
+ZT6.4.2e benzodiazepines qh ah |
ZJ2.6.10.2.2.2.2e | . . . . . . baclofen qh |
ZJ2.6.10.2.2.4e | . . . . . endothelin qh |
HN | Introduced 1995. | |
BT | +YMe other biological factors qh ah |
ZJ2.6.10.2.4e | . . . . hydroxybutyrate qh |
BT | +ZJ2.10.4e hydroxy acids qh ah |
ZJ2.6.10.2.4.2e | . . . . . sodium oxybate qh |
BT | +YR4e anesthetics qh ah | |
+YW4.4e general anesthetics qh ah |
ZJ2.6.10.4e | . . . carbamates qh |
ZJ2.6.10.4.2e | . . . . meprobamate qh |
SN | One of the (antianxiety) tranquilizers used for muscle relaxation and sedation. Meprobamate is less potent than the minor tranquilizers derived from benzodiazepine such as chlordiazepoxide hydrochloride (Librium) and diazepam (Valium). Manufactured as Miltown and Equanil. | |
BT | +BT6.8.2 schedule IV CNS depressants qh ah | |
+YT6.2 central muscle relaxants qh ah | ||
+YW4.8e sedative-hypnotics qh ah | ||
+YW4.8.6e antianxiety tranquilizers qh ah |
ZJ2.6.10.4.4e | . . . . thiocarbamates qh |
ZJ2.6.10.4.4.2e | . . . . . diethylthiocarbamate qh |
ZJ2.6.10.4.4.2.2e | . . . . . . disulfiram qh |
SN | The prototypic alcohol-sensitizing drug prescribed to assist in maintaining abstinence from alcohol. Disulfiram inhibits aldehyde dehydrogenase activity and, in the presence of alcohol, causes accumulation of acetaldehyde and an aversive facial flushing reaction accompanied by nausea, dizziness, and palpitations. These effects are sometimes termed "the Antabuse reaction". | |
ST | Antabuse | |
NT | HK2.12.2.2 disulfiram therapy qh ah | |
BT | +YD8.2 ADH antagonists qh ah | |
+YP4.2e anti-alcohol-intoxication agents qh ah | ||
+YP4.8.8e alcohol deterrents qh ah | ||
RT | +ZG2.4e acetaldehyde qh ah |
ZJ2.6.10.4.4.4e | . . . . . dimethyldithiocarbamate qh |
ZJ2.6.10.4.4.4.2e | . . . . . . thiram qh |
BT | +YQ4.2 local anti-infective agents qh ah | |
+YQ4.8 antifungal agents qh ah | ||
+YX10.4.4 industrial fungicides qh ah |
ZJ2.6.10.4.6e | . . . . urethane qh |
BT | +YD8.2 ADH antagonists qh ah | |
+YQ6 antineoplastic agents qh ah |
ZJ2.6.12e | . . valeric acid qh |
ST | pentanoic acid | |
BT | +ZK4.8e volatile fatty acid qh ah |
ZJ2.6.12.2e | . . . valerate qh |
ZJ2.6.12.2.2e | . . . . valproate qh |
BT | +YW4.6e anticonvulsants qh ah |
ZJ2.6.14e | . . caproic acid qh |
ST | hexanoic acid | |
BT | +ZK4.8e volatile fatty acid qh ah |
ZJ2.6.14.2e | . . . penicillic acid qh |
BT | +YX2.12 mycotoxins qh ah | |
+YX4e carcinogens qh ah |
ZJ2.6.14.4e | . . . caproate qh |
ZJ2.6.20e | . . capric acid qh |
ST | decanoic acid | |
BT | +ZK4e fatty acids qh ah |
ZJ2.6.22e | . . lauric acid qh |
ST | dodecanoic acid | |
BT | +ZK4e fatty acids qh ah |
ZJ2.6.24e | . . myristic acid qh |
ST | tetradecanoic acid | |
BT | +ZK4e fatty acids qh ah |
ZJ2.6.26e | . . palmitic acid qh |
ST | hexadecanoic acid | |
BT | +ZK4e fatty acids qh ah |
ZJ2.6.26.2e | . . . palmitate qh |
ZJ2.6.28e | . . stearic acid qh |
ST | octadecanoic acid | |
BT | +ZK4e fatty acids qh ah |
ZJ2.6.28.2e | . . . stearate qh |
ZJ2.6.30e | . . eicosanoic acid qh |
ST | arachidic acid | |
BT | +ZK4e fatty acids qh ah |
ZJ2.8e | . unsaturated carboxylic acid qh |
NT | +ZK4.4e unsaturated fatty acids qh ah |
ZJ2.8.2 | . . monounsaturated carboxylic acid qh |
HN | Introduced 1995. |
ZJ2.8.4 | . . polyunsaturated carboxylic acid qh |
HN | Introduced 1995. | |
NT | +ZK4.4.2.2e arachidonic acid qh ah | |
ZK4.4.4e linoleic acid qh ah | ||
ZK4.4.6.2e linolenic acid qh ah |
ZJ2.10e | . substituted carboxylic acid qh |
ZJ2.10.2e | . . halogen substituted acid qh |
ZJ2.10.4e | . . hydroxy acids qh |
NT | +ZG8.4e sugar acids qh ah | |
+ZJ2.6.10.2.4e hydroxybutyrate qh ah | ||
+ZJ2.10.10.2.4e hydroxybenzoic acid qh ah | ||
RT | +ZO2e amino acids qh ah |
ZJ2.10.4.2e | . . . gamma-hydroxybutyric acid qh |
BT | +YP4.8.2.6 GABA receptor agonist anti-alcohol-craving agents qh ah |
ZJ2.10.4.4e | . . . benzilate qh |
ZJ2.10.4.4.2e | . . . . quinuclidinyl benzilate qh |
BT | +YV8e parasympatholytics qh ah | |
+ZT12.2e quinuclidine qh ah |
ZJ2.10.4.6e | . . . glycolate qh |
ST | glycolic acid |
ZJ2.10.4.8e | . . . methylphenidate qh |
SN | A CNS stimulant similar to amphetamines that is often prescribed for the treatment of hyperkinesis in children and for weight control in adults. Manufactured as Ritalin. | |
ST | methylphenidate hydrochloride | |
Ritalin | ||
BT | +BT6.4.6 schedule II CNS stimulants qh ah | |
+YP10.8.10.6 agents for cocaine-related cognitive impairment qh ah |
ZJ2.10.4.10e | . . . phosphoenolpyruvate qh |
BT | +EB4.2 high-energy compound qh ah | |
RT | YC10.10.6 phosphoenolpyruvate carboxykinase qh ah |
ZJ2.10.6e | . . keto acids qh |
NT | +ZG4e ketones qh ah | |
ZJ2.12.2.2.2e oxaloacetate qh ah | ||
+ZN2.20.6.2e hippurates qh ah |
ZJ2.10.6.2e | . . . acetoacetic acid qh |
ZJ2.10.6.2.2e | . . . . acetoacetate qh |
ZJ2.10.6.4e | . . . levulinic acid qh |
ZJ2.10.6.4.2e | . . . . aminolevulinic acid qh |
RT | YC10.14.2 aminolevulinic acid dehydratase qh ah |
ZJ2.10.6.6e | . . . pyruvate qh |
RT | YC8.6 pyruvate carboxylase qh ah | |
YC10.10.10 pyruvate decarboxylase qh ah | ||
YC14.12.2 pyruvate oxidase qh ah | ||
YC16.14.6.16e pyruvate kinase qh ah |
ZJ2.10.8e | . . organic sulfur acids qh |
ST | sulfur acids (organic) | |
BT | +ZR4e organic sulfur compounds qh ah |
ZJ2.10.8.2e | . . . sulfonic acid qh |
ZJ2.10.8.2.2e | . . . . alkyl sulfonate qh |
ZJ2.10.8.2.2.2e | . . . . . taurine qh |
NT | ZV10.2.4e taurocholic acid qh ah | |
BT | +BJ2.2e amphetamines qh ah | |
+YJ2e neurotransmitters qh ah |
ZJ2.10.8.2.2.2.2e | . . . . . . calcium acetylhomotaurinate qh |
HN | Introduced 1995. | |
ST | Acamprosate | |
BT | +YP4.8.2.6 GABA receptor agonist anti-alcohol-craving agents qh ah |
ZJ2.10.8.2.2.2.4e | . . . . . . bis acetyl homotaurine qh |
BT | +YP4.8.2.6 GABA receptor agonist anti-alcohol-craving agents qh ah |
ZJ2.10.10e | . . aromatic carboxylic acid qh |
ST | carbocyclic acid |
ZJ2.10.10.2e | . . . benzoic acid qh |
NT | +ZN2.20.6e benzamides qh ah |
ZJ2.10.10.2.2e | . . . . aminobenzoic acid qh |
BT | +YB12e vitamin B complex qh ah |
ZJ2.10.10.2.2.2e | . . . . . 4-aminobenzoic acid qh |
ZJ2.10.10.2.2.2.2e | . . . . . . procainamide qh |
BT | +YT8.2 antiarrhythmia agents qh ah |
ZJ2.10.10.2.2.2.4e | . . . . . . procaine qh |
BT | +YR4.2e local anesthetics qh ah |
ZJ2.10.10.2.4e | . . . . hydroxybenzoic acid qh |
BT | +ZF4e phenols qh ah | |
+ZJ2.10.4e hydroxy acids qh ah |
ZJ2.10.10.2.4.2e | . . . . . salicylic acid qh |
ZJ2.10.10.2.4.2.2e | . . . . . . acetylsalicylic acid qh |
ST | aspirin | |
BT | +YT14.6 platelet aggregation inhibitors qh ah |
ZJ2.10.10.2.4.2.4e | . . . . . . salicylate qh |
BT | +YQ2.2 nonsteroidal anti-inflammatory drugs qh ah | |
+YR2.2 nonnarcotic analgesics qh ah |
ZJ2.10.10.2.4.2.4.2e | . . . . . . . sodium salicylate qh |
ZJ2.10.10.2.6e | . . . . lactate qh |
RT | +YC14.2.4.6e lactate dehydrogenases qh ah |
ZJ2.10.10.4e | . . . cyclohexanecarboxylic acid qh |
ZJ2.10.10.4.2e | . . . . tilidine qh |
BT | +BT6.2.8.2 schedule I opiates qh ah | |
+YR2e analgesics qh ah |
ZJ2.10.10.6e | . . . phthalic acid qh |
ZJ2.10.10.6.2e | . . . . phthalimide qh |
ZJ2.10.10.6.2.2e | . . . . . thalidomide qh |
BT | +YQ4.6.2 leprostatic agents qh ah | |
+YW4.8.4e nonbarbiturate sedative-hypnotics qh ah | ||
+YX6e teratogens qh ah | ||
+ZT4.20.8e piperidone qh ah |
ZJ2.10.10.6.4e | . . . . phenylacetates qh |
HN | Introduced 2000. |
ZJ2.10.10.6.4.2e | . . . . . dihydroxyphenylacetic acid qh |
HN | Introduced 2000. | |
ST | DOPAC | |
homoprotocatechuic acid |
ZJ2.12e | . polycarboxylic acid qh |
ZJ2.12.2e | . . dicarboxylic acid qh |
ZJ2.12.2.2e | . . . oxalate qh |
ZJ2.12.2.2.2e | . . . . oxaloacetate qh |
BT | +ZJ2.10.6e keto acids qh ah |
ZJ2.12.2.4e | . . . succinate qh |
NT | +ZN2.16.2.10.2e succinylcholine qh ah | |
ZN6.2e succinimide qh ah | ||
RT | YC14.32 succinate dehydrogenase qh ah |
ZJ2.12.4e | . . tricarboxylic acid qh |
RT | EB4.6 tricarboxylic acid cycle qh ah |
ZJ4 | carboxylic acid derivatives qh |
ZJ4.2e | . esters qh |
RT | +BX2.2.4e congener qh ah | |
CM30.2 esterification qh ah |
ZJ4.8e | . nitrogen-containing carboxylic acid derivative qh |
NT | +ZN2.20.2e amides qh ah |
ZJ4.8.2e | . . nitriles qh |
BT | +ZMe organic nitrogen compounds qh ah | |
RT | +ZC12.6e cyanide qh ah |
ZJ4.8.4e | . . hydrazides qh |
RT | ZF6.4e hydrazine qh ah |
ZJ4.8.6e | . . azide qh |
ZK | lipids, fatty acids, fats and oils d-out qh |
SN | Lipids contain fats and fatty acids. | |
NT | EB14e lipid metabolism qh ah | |
+ZO6.8.18e lipoproteins qh ah | ||
ZO6.8.28e proteolipid qh ah | ||
+ZV12.4e sterols qh ah | ||
BT | +ZJ carboxylic acids and derivatives qh ah | |
RT | +GH14.4e nutritional deficiency qh ah | |
+YAe nutrients qh ah |
ZK2e | . lipids qh |
NT | +GR6e lipid metabolism disorder qh ah |
ZK2.2e | . . glycolipids qh |
ZK2.2.2e | . . . ganglioside qh |
ZK2.2.4e | . . . phosphoinositide qh |
RT | YC4.6.4.6.2 phospholipase C qh ah | |
+ZF2.12.4.2e inositol phosphate qh ah |
ZK2.4e | . . phospholipids qh |
ZK2.4.2e | . . . glycerophosphate qh |
ZK2.4.2.2e | . . . . phosphatidic acid qh |
ZK2.4.2.2.2e | . . . . . phosphatidylcholine qh |
ST | lecithin | |
phosphatidyl choline |
ZK2.4.2.2.4e | . . . . . phosphatidylethanol qh |
HN | Introduced 2000. | |
BT | +HB4.6.2.2e AODR biochemical markers qh ah |
ZK2.4.2.2.4.2e | . . . . . . phosphatidylethanolamine qh |
ST | PE | |
phosphatidyl ethanolamine | ||
BT | +ZN2e amines qh ah |
ZK2.4.2.2.6e | . . . . . phosphatidylinositol qh |
ST | inositol phospholipid | |
phosphatidyl inositol | ||
RT | +ZF2.12.4.2e inositol phosphate qh ah |
ZK2.4.2.2.6.2e | . . . . . . phosphatidylinositol phosphate qh |
ST | phosphatidylinositol biphosphate | |
phosphatidylinositol bisphosphate |
ZK2.4.2.2.8e | . . . . . phosphatidylserine qh |
ST | phosphatidyl serine |
ZK2.4.2.4e | . . . . phospholipid ether qh |
BT | +ZF6e ethers qh ah |
ZK2.4.2.4.2e | . . . . . plasmalogen qh |
ZK2.4.2.4.4e | . . . . . platelet-activating factor qh |
BT | +YE10e cytokines qh ah | |
+ZO6.4.10.6.4e blood coagulation factors qh ah |
ZK2.4.4e | . . . liposomes qh |
HN | Introduced 2000. | |
RT | XA2.12.10 membrane layer qh ah |
ZK2.6e | . . sphingolipids qh |
ZK2.6.2e | . . . ceramide qh |
ZK2.6.2.2e | . . . . sphingomyelin qh |
ZK4e | . fatty acids qh |
NT | ZJ2.6.20e capric acid qh ah | |
ZJ2.6.22e lauric acid qh ah | ||
ZJ2.6.24e myristic acid qh ah | ||
+ZJ2.6.26e palmitic acid qh ah | ||
+ZJ2.6.28e stearic acid qh ah | ||
ZJ2.6.30e eicosanoic acid qh ah | ||
RT | YC14.10.2 fatty acid desaturases qh ah |
ZK4.2e | . . fatty acid ethyl esters qh |
HN | Introduced 2000. | |
ST | FAEE |
ZK4.4e | . . unsaturated fatty acids qh |
BT | +ZJ2.8e unsaturated carboxylic acid qh ah |
ZK4.4.2e | . . . eicosanoids qh |
SN | Class of substances that exhibit a wide range of biologic activity. | |
NT | +ZK4.4.8e prostaglandins qh ah | |
ZK4.6e thromboxane qh ah |
ZK4.4.2.2e | . . . . arachidonic acid qh |
BT | +ZJ2.8.4 polyunsaturated carboxylic acid qh ah |
ZK4.4.2.2.2e | . . . . . leukotrienes qh |
ZK4.4.4e | . . . linoleic acid qh |
BT | +ZJ2.8.4 polyunsaturated carboxylic acid qh ah |
ZK4.4.6e | . . . omega-3 fatty acid qh |
ZK4.4.6.2e | . . . . linolenic acid qh |
BT | +ZJ2.8.4 polyunsaturated carboxylic acid qh ah |
ZK4.4.8e | . . . prostaglandins qh |
NT | YM14.2 prostaglandin antagonists qh ah | |
BT | +YM14 slow-reacting substances qh ah | |
+ZK4.4.2e eicosanoids qh ah | ||
RT | XU2 diffuse endocrine system qh ah | |
YC12.2e prostaglandin synthase qh ah |
ZK4.4.8.2e | . . . . prostacyclin qh |
HN | Introduced 1995. | |
ST | epoprostenol | |
PGI2 | ||
PGX | ||
prostaglandin I2 | ||
prostaglandin X | ||
BT | +YT14.6 platelet aggregation inhibitors qh ah |
ZK4.4.8.4e | . . . . prostaglandin endoperoxide qh |
ZK4.4.8.6e | . . . . synthetic prostaglandin qh |
ZK4.4.8.6.2e | . . . . . misoprostol qh |
HN | Introduced 1995. | |
BT | +YS reproductive control agents qh ah | |
+YT10.8 antiulcer agents qh ah |
ZK4.6e | . . thromboxane qh |
BT | +YM14 slow-reacting substances qh ah | |
+ZK4.4.2e eicosanoids qh ah | ||
RT | YC6.6 thromboxane synthetase qh ah |
ZK4.8e | . . volatile fatty acid qh |
NT | +ZJ2.6.4e acetic acid qh ah | |
+ZJ2.6.6e propionic acid qh ah | ||
+ZJ2.6.10e butyric acid qh ah | ||
+ZJ2.6.12e valeric acid qh ah | ||
+ZJ2.6.14e caproic acid qh ah |
ZK4.10e | . . prostanoic acid qh |
ZK4.12e | . . sodium morrhuate qh |
ZK6e | . glycerides qh |
ZK6.2e | . . diglycerides qh |
ST | diacylglycerol | |
BT | +YM2.4e intracellular messengers qh ah | |
RT | +YM2.2e second messengers qh ah | |
ZO6.6.12.2.6e G q/11 alpha qh ah |
ZK6.4e | . . triglycerides qh |
ZK6.4.2e | . . . triolein qh |
BT | +ZK8.4e unsaturated fat qh ah |
ZK8e | . fats qh |
RT | +ZK10e oils qh ah |
ZK8.2e | . . dietary fats qh |
ZK8.4e | . . unsaturated fat qh |
NT | ZK6.4.2e triolein qh ah |
ZK10e | . oils qh |
RT | +ZK8e fats qh ah |
ZK10.2 | . . plant oil qh |
HN | Introduced 1995. |
ZK10.2.2 | . . . croton oil qh |
HN | Introduced 1995. | |
NT | +ZU10.4.2e phorbol ester qh ah | |
BT | +YX4e carcinogens qh ah |
ZL | organic halogen compounds d-out qh |
BT | +ZDe organic compounds qh ah |
ZL2e | halogenated hydrocarbons qh |
BT | +ZEe hydrocarbons qh ah |
ZL2.2e | . fluorocarbons qh |
SN | A large group of chlorinated or fluorinated hydrocarbons now used chiefly as refrigerants. Prior to 1978, they were widely used as aerosol propellants in household products and were subject to abuse because of their intoxicating (anesthetic) effects when inhaled. Fluorocarbons and chlorofluorocarbons were banned from use in household consumer products on March 16, 1978, by the U.S. Environmental Protection Agency under the Toxic Substance Control Act of 1976. The aerosol propellants currently used by industry are pentane, pentene, and other such hydrocarbons. Because of their flammability, they are believed to pose more of a safety than health threat to society. | |
ST | fluorinated hydrocarbons | |
BT | +BG4 aerosol propellant of abuse qh ah |
ZL2.2.2e | . . freon qh |
RT | +BGe volatile inhalant qh ah |
ZL2.4e | . halothane qh |
RT | +YW4.8e sedative-hypnotics qh ah |
ZL2.6e | . chlorinated hydrocarbons qh |
ZL2.6.2e | . . carbon tetrachloride qh |
SN | A highly toxic, chlorinated hydrocarbon liquid that was widely used at one time as a solvent in cleaning fluids and, when inhaled, produced intoxication. Toxic reactions include headache, confusion, depression, fatigue, nausea, vomiting, and death. Both the vapor and the liquid irritate skin and eyes. | |
BT | +BG2 solvent of abuse qh ah |
ZL2.6.4e | . . chloroform qh |
SN | A vaporous anesthetic depressant similar to ether that is capable of producing an alcohol-like intoxication when inhaled. Never very popular, chloroform is known to be more frequently fatal than any of the other anesthetics or alcohol. It also is used as a solvent. | |
ST | trichloromethane | |
BT | +YR4e anesthetics qh ah | |
+YW4.4e general anesthetics qh ah | ||
RT | +BGe volatile inhalant qh ah |
ZL2.6.6e | . . trichloroethane qh |
ZL2.6.8e | . . trichloroethylene qh |
HN | Introduced 1995. | |
ST | ethinyl trichloride | |
BT | +YR4e anesthetics qh ah |
ZL2.8e | . mustard compounds qh |
ZL4e | halogenated steroids qh |
BT | +ZVe steroids qh ah |
ZL4.4e | . fluorinated steroids qh |
NT | YH4.6.2.2e dexamethasone qh ah |
classification thesaurus glossary dictionary definition subject heading list ontology vocabulary knowledge structure knowledge organization terminology concept